New CAR T-cell Clinical Trials in the United States Have Extended Enrollment to Canadian Myeloma Patients!
We are seeing some very promising results with Chimeric antigen receptor (CAR) T-cell therapy in early ph...
Read moreResearch & Access Updates
New Drug Reimbursement Recommendation for Pomalyst
The Canadian Agency for Drugs and Technologies in Health recommanded the reimbursement for Pomalidomide (...
Read moreThe 10th Edition of the Myeloma Canada Scientific Roundtable was a Great Success
On October 4th and 5th, leading hematologists and myeloma researchers from around the country and the Uni...
Read moreDaratumumab (Darzalex) is Now Available in Newfoundland
As of Aug 16, 2019, Darzalex has been approved in Newfoundland, in combination with Lenalidomide and Dexa...
Read moreDarzalex Now Listed in Saskatchewan!
As of July 15, Darzalex (daratumumab) has been approved in Saskatchewan, in combination with lenalidomide...
Read moreHealth Canada Approves Pomalyst-Based Triplet Combination
On July 10, 2019, Celgene Inc. announced that Health Canada...
Read more